CoChat

Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial

Metin, Özmen, Yazici, Kemal, Tot, Senel, Yazici, Aylin Ertekin · 2003 · Human Psychopharmacology: Clinical and Experimental
Cited by 68

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Despite the effectiveness of clomipramine and selective serotonin reuptake inhibitors (SSRIs) in the treatment of obsessive–compulsive disorder (OCD), 40% to 60% of patients who receive an adequate treatment with these agents have significant persisting symptoms. Newer atypical antipsychotic drugs showed efficacy as augmenting agents in patients with OCD resistant to serotonin reuptake inhibitors (SRIs). The objective of this study was to evaluate the efficacy and safety of amisulpiride augmentation in treatment resistant OCD. A total of 20 patients diagnosed with OCD according to DSM‐IV criteria and having a history of resistance to treatment with SRIs were included in the study. Amisulpiride 200 mg/day was added to ongoing SRI treatment and titrated up to 600 mg/day in flexible doses. The mean amisulpiride dose was 325 ± 106 mg/day. The patients were assessed with the Yale‐Brown obsessive‐compulsive scale (Y‐BOCS) at baseline and at week 12 of amisulpiride treatment. Side effects were monitored by the UKU side effect rating scale. The reduction in Y‐BOCS scores between the baseline (26.7 ± 6.3) and the end of the treatment (12.5 ± 2.8) was statistically significant (p = 0.0001). The most commonly observed side effects included weight gain (14 patients, 70%), mild sedation (13 patients, 65%) and asthenia (7 patients, 35%). This study has several limitations and, hence, the results are preliminary and require confirmation in a randomized controlled trial. In conclusion, this study suggests that amisulpiride may be a promising option as an augmentation strategy in treatment resistant OCD. Copyright © 2003 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hup.512

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 68

Metadata

Authors
Metin, Ö., Yazici, K., Tot, S., & Yazici, A. E.
Venue
Human Psychopharmacology: Clinical and Experimental
Publisher
Wiley
Published
2003-08
Volume
18
Issue
6
Pages
463-467
ISSN
  • 0885-6222 (ISSN-L)
  • 1099-1077
OpenAlex
W1982472872
Cited by
68
References
6
FWCI
5.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial. https://app.cochat.ai/papers/10.1002/hup.512
The paper
Metin, Ö., Yazici, K., Tot, S., & Yazici, A. E. (2003). Amisulpiride augmentation in treatment resistant obsessive–compulsive disorder: an open trial. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.512

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.